Prostate cancer in renal transplant recipients

14Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

Abstract

As patients with end-stage renal disease are receiving renal allografts at older ages, the number of male renal transplant recipients (RTRs) being diagnosed with prostate cancer (CaP) is increasing. Historically, the literature regarding the management of CaP in RTR's is limited to case reports and small case series. To date, there are no standardized guidelines for screening or management of CaP in these complex patients. To better understand the unique characteristics of CaP in the renal transplant population, we performed a literature review of PubMed, without date limitations, using a combination of search terms including prostate cancer, end stage renal disease, renal transplantation, prostate cancer screening, prostate specific antigen kinetics, immunosuppression, prostatectomy, and radiation therapy. Of special note, teams facilitating the care of these complex patients must carefully and meticulously consider the altered anatomy for surgical and radiotherapeutic planning. Active surveillance, though gaining popularity in the general low risk prostate cancer population, needs further study in this group, as does the management of advance disease. This review provides a comprehensive and contemporary understanding of the incidence, screening measures, risk stratification, and treatment options for CaP in RTRs.

Cite

CITATION STYLE

APA

Sherer, B. A., Warrior, K., Godlewski, K., Hertl, M., Olaitan, O., Nehra, A., & Deane, L. A. (2017, November 1). Prostate cancer in renal transplant recipients. International Braz J Urol. Brazilian Society of Urology. https://doi.org/10.1590/S1677-5538.IBJU.2016.0510

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free